沙美特罗替卡松粉吸入剂对哮喘-慢性阻塞性肺疾病重叠综合征患者肺功能心率变异性及肿瘤坏死因子相关蛋白的影响分析  

Effects of salmeterol/fluticasone powder inhalation on lung function,heart rate variability and tumor necrosis factor-related proteins in patients with ACOS

作　　者：席贝贝 武梦佳 余翠果 Xi Beibei;Wu Mengjia;Yu Cuiguo(Department of Pharmacy,Ruzhou First People′s Hospital,Henan467599,China)

机构地区：[1]河南省汝州市第一人民医院药剂科,467599

出　　处：《中国药物与临床》2022年第3期238-241,共4页Chinese Remedies & Clinics

摘　　要：目的探究沙美特罗替卡松粉吸入剂对哮喘-慢性阻塞性肺疾病重叠综合征(ACOS)患者肺功能、心率变异性及肿瘤坏死因子(CTRP)相关蛋白的影响。方法选取汝州市第一人民医院2018年12月至2020年11月128例ACOS患者作为研究对象,依据治疗药物不同分为对照组和观察组。对照组64例给予小剂量阿奇霉素联合噻托溴铵粉吸入剂治疗,观察组64例增加沙美特罗替卡松粉吸入剂,对比2组患者肺功能、心率变异性及肿瘤坏死因子相关蛋白,药物安全性。结果2组患者治疗3个月末第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、第1秒用力呼气容积与用力肺活量比值(FEV1/FVC)水平较治疗前均升高,观察组高于对照组(P<0.05)。2组患者治疗3个月末24 h正常RR间期标准差(SDNN)、连续5 min正常RR间期差值的均方根值(RMSSD)水平较治疗前均升高,观察组高于对照组(P<0.05)。2组患者治疗3个月末CTRP-4、CTRP-5水平较治疗前均降低,观察组低于对照组(P<0.05)。观察组不良反应率6%(4/64)高于对照组3%(2/64),差异无统计学意义(P>0.05)。结论沙美特罗替卡松粉吸入剂治疗ACOS患者,通过减轻压力感受器所受到的异常刺激,调控心率变异性水平,调节肺功能,改善CTRP水平,安全性较高,提高临床疗效。Objective To investigate the effects of salmeterol/fluticasone powder inhalation on lung func-tion,heart rate variability,and tumor necrosis factor-related proteins in patients with asthma-chronic obstructive pulmonary disease overlap syndrome(ACOS).Methods A total of 128 ACOS patients in Ruzhou First People′s Hospital between December 2018 and November 2020 were included as study subjects and were divided into the control group(n=64)and study group(n=64)according to different treatments.The control group were treated with low-dose azithromycin combined with tiotropium powder inhalation,and the study group were treated with salme-terol fluticasone powder inhalation.The lung function,heart rate variability,tumor necrosis factor-related proteins,and drug safety were compared between the two groups.Results The levels of forced expiratory volume in the first second(FEV1),forced vital capacity(FVC),and the ratio of forced expiratory volume in the first second to forced vital capacity(FEV1/FVC)in either group at the end of three months of treatment were all higher than baseline,and these increases were greater in the study group compared with the control group(P<0.05).The 24-hour standard deviation of the normal-to-normal RR interval(SDNN)and the 5-min root mean square of squared differences between successive RR intervals(RMSSD)in either group at the end of three months of treatment were all higher than baseline,and these increases were greater in the study group compared with the control group(P<0.05).The levels of C1q and tumor necrosis factor-related protein 4(CTRP-4)and CTRP-5 in either group at the end of three months of treatment were lower than baseline,and these reductions were greater in the study group compared with the control group(P<0.05).The rate adverse reactions was 6%(4/64)in the study group,which was higher than that of the control group[3%(2/64)]but with no statistical difference(P>0.05).Conclusion Salme-terol fluticasone powder inhalation as a treatment for patients with ACOS can improve heart ra

关 键 词：氟替卡松-沙美特罗复方合剂 哮喘-慢性阻塞性肺疾病重叠综合征 呼吸功能试验 

分 类 号：R563.9[医药卫生—呼吸系统]